These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16224180)

  • 1. Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
    Kurosaki I; Hatakeyama K
    Chemotherapy; 2005 Oct; 51(6):305-10. PubMed ID: 16224180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine in node-positive pancreatic cancer.
    Kurosaki I; Hatakeyama K
    Hepatogastroenterology; 2004; 51(57):634-7. PubMed ID: 15143880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of postoperative adjuvant chemotherapy with gemcitabine for pancreatic cancer: feasibility and anti-tumor effect].
    Kurosaki I; Tsuchiya Y; Shimizu T; Hatakeyama K
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1201-4. PubMed ID: 15332543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
    Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
    JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
    Oettle H; Neuhaus P; Hochhaus A; Hartmann JT; Gellert K; Ridwelski K; Niedergethmann M; Zülke C; Fahlke J; Arning MB; Sinn M; Hinke A; Riess H
    JAMA; 2013 Oct; 310(14):1473-81. PubMed ID: 24104372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
    Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K
    Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.
    Ozkok S; Demirci S; Yalman D; Zeytunlu M; Nart D; Yuzer Y; Coker A; Goker E
    Tumori; 2010; 96(4):560-7. PubMed ID: 20968135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
    J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
    Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
    Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
    Cantore M; Serio G; Pederzoli P; Mambrini A; Iacono C; Pulica C; Capelli P; Lombardi M; Torri T; Pacetti P; Pagani M; Fiorentini G
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):504-8. PubMed ID: 16633830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
    Van Laethem JL; Hammel P; Mornex F; Azria D; Van Tienhoven G; Vergauwe P; Peeters M; Polus M; Praet M; Mauer M; Collette L; Budach V; Lutz M; Van Cutsem E; Haustermans K
    J Clin Oncol; 2010 Oct; 28(29):4450-6. PubMed ID: 20837948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.
    Ueno H; Kosuge T; Matsuyama Y; Yamamoto J; Nakao A; Egawa S; Doi R; Monden M; Hatori T; Tanaka M; Shimada M; Kanemitsu K
    Br J Cancer; 2009 Sep; 101(6):908-15. PubMed ID: 19690548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
    Sumii T; Funakoshi A; Ito T; Mizumoto K; Tanaka M; Migita Y; Sakai T; Shinozaki H; Yamaguchi H; Niyahara T; Muranaka T; Eriguchi N; Ueki T;
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):971-6. PubMed ID: 12894712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.
    Fischer R; Breidert M; Keck T; Makowiec F; Lohrmann C; Harder J
    Saudi J Gastroenterol; 2012; 18(2):118-21. PubMed ID: 22421717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
    Shimoda M; Kubota K; Shimizu T; Katoh M
    Br J Surg; 2015 Jun; 102(7):746-54. PubMed ID: 25833230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
    Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
    Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.